Microneedling treatment for burn scars
Randomized Controlled Evaluator-blinded Trial of Microneedling for the Treatment of Hypertrophic Scars of Adult Burn Survivors and Patients With Severe Skin Disorders
This study tests if microneedling combined with cortisone can improve the appearance of thick, red scars from severe burns in patients with multiple scars.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 36 (estimated) |
| Ages | 16 Years to 100 Years |
| Sex | All |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) Academic / other |
| Locations | 1 site (Montréal) |
| Trial ID | NCT05423613 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of microneedling in improving hypertrophic scars resulting from severe burns. Patients will undergo up to five microneedling treatments, spaced six weeks apart, followed by the application of cortisone to enhance scar healing. The microneedling technique creates microchannels in the skin, which may increase the absorption of the cortisone, potentially leading to better outcomes in scar pliability, thickness, and redness. The study aims to assess these improvements in patients with multiple hypertrophic scars.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 16 and older with at least two hypertrophic scars.
Not a fit: Patients with keloid scars or other dermatological conditions affecting the evaluation site may not benefit from this treatment.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the appearance and symptoms of hypertrophic scars in burn victims, enhancing their quality of life.
How similar studies have performed: While microneedling has shown promise in other dermatological applications, this specific approach for hypertrophic scars is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any gender or race * 16 years of age or older * Have at least 2 HSc that meet the clinical criteria for HSc * Provide written informed consent. Exclusion Criteria: * Patients with keloid scars * Mature scar site * A psychiatric condition or cognitive impairment that interferes with their ability to follow the treatment protocol * Dermatological conditions (i.e. psoriasis, eczema, etc.) in the area of the evaluation site * An allergy to ultrasound gel * On anticoagulant medications * Inability to understand English or French.
Where this trial is running
Montréal
- Villa Medica Rehabilitation Hospital — Montréal, Canada (Recruiting)
Study contacts
- Study coordinator: Bernadette Nedelec
- Email: bernadette.nedelec@mcgill.ca
- Phone: 514-398-1275
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.